Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 131 articles: HTML format

Single Articles

August 2026
1. HILL H, Roadevin C
   Economic evaluation of artificial intelligence for cancer detection in the UK breast screening programme.
   Br J Cancer. 2026;135:453-460.
   PubMed     Abstract available
   
   
   
2. LOPEZ MUJICA MEJ, Boonkaew S, Christensen NL, Abildgaard Pedersen M, et al
   Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.
   Br J Cancer. 2026;135:649-658.
   PubMed     Abstract available
   
   
   
3. LI SJ, Brentnall AR, Cookson J, Hudson S, et al
   The effect of different combinations of open invitations and timed appointments on breast screening attendance: service evaluation of invitation strategies in the NHS Breast Screening Programme.
   Br J Cancer. 2026;135:630-640.
   PubMed     Abstract available
   
   
   
4. KANG MS, Katuwal NB, Ghosh M, Hong SD, et al
   JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
   Br J Cancer. 2026;135:503-517.
   PubMed     Abstract available
   
   
   July 2026
5. JEONG JY, Kim CY, Nam AR, Cho JY, et al
   FGFR4-associated APOBEC3 mutagenesis characterizes HER2-enriched subtype of human breast cancer.
   Br J Cancer. 2026 Jul 27. doi: 10.1038/s41416-026-03517.
   PubMed     Abstract available
   
   
   
6. JORGENSEN KJ, Brodersen JB
   Risk-based breast cancer screening.
   Br J Cancer. 2026 Jul 17. doi: 10.1038/s41416-026-03557.
   PubMed    
   
   
   
7. ALIU AE, Kerrison RS, Marcu A
   Black women's decisions about participating in breast cancer screening in the UK: a qualitative study.
   Br J Cancer. 2026 Jul 16. doi: 10.1038/s41416-026-03551.
   PubMed     Abstract available
   
   
   June 2026
8. ROMANOS-NANCLARES A, Bui LP, Rosner BA, Willett WC, et al
   Planetary Health Diet Index and breast cancer risk.
   Br J Cancer. 2026 Jun 30. doi: 10.1038/s41416-026-03523.
   PubMed     Abstract available
   
   
   
9. METCALFE K, Narod SA, Poll A, Hoey C, et al
   Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer.
   Br J Cancer. 2026 Jun 23. doi: 10.1038/s41416-026-03502.
   PubMed     Abstract available
   
   
   
10. CHIRIKOVA E, Ronckers CM, Little MP, Quinn E, et al
    Breast cancer incidence and mortality in population studies of radiation exposure: systematic review and meta-analysis.
    Br J Cancer. 2026 Jun 16. doi: 10.1038/s41416-026-03503.
    PubMed     Abstract available
    
    
    
11. CHIN JH, Kim D, Lee HS, Jeon S, et al
    Adjuvant radiotherapy and skin cancer risk in breast cancer survivors: a nationwide cohort study in Korea.
    Br J Cancer. 2026 Jun 12. doi: 10.1038/s41416-026-03485.
    PubMed     Abstract available
    
    
    
12. BOJESEN SE
    Risk-based breast cancer screening.
    Br J Cancer. 2026 Jun 3. doi: 10.1038/s41416-026-03489.
    PubMed    
    
    
    
13. MICHAEL A, Huynh J, Sutton K, Chow MC, et al
    The utility of electronic frailty index in cancer patients undergoing chemotherapy.
    Br J Cancer. 2026;134:1793-1800.
    PubMed     Abstract available
    
    
    May 2026
14. KAVIANI A, Karkeabadi N, Farazmand B
    Primary tumour resection in de novo stage IV breast cancer: considerations from the PRIM-BC trial.
    Br J Cancer. 2026 May 20. doi: 10.1038/s41416-026-03469.
    PubMed    
    
    
    
15. KAHOUNOVA Z, Hruskova M, Drapela S, Naar O, et al
    Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer.
    Br J Cancer. 2026 May 18. doi: 10.1038/s41416-026-03468.
    PubMed     Abstract available
    
    
    
16. YANG K, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Diabetes mellitus and health-related quality of life in long-term survivors of breast, colorectal or prostate cancer: a population-based prospective study.
    Br J Cancer. 2026 May 13. doi: 10.1038/s41416-026-03463.
    PubMed     Abstract available
    
    
    
17. METSER U, Dayes IS, Parpia S, Eisen AF, et al
    Prospective study on (18)F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.
    Br J Cancer. 2026;134:1387-1392.
    PubMed     Abstract available
    
    
    April 2026
18. VALACHIS A, Geisler J, Karihtala P, Tuxen MK, et al
    Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence?
    Br J Cancer. 2026 Apr 29. doi: 10.1038/s41416-026-03452.
    PubMed     Abstract available
    
    
    
19. AHMAD S, Butle A, Karn A, Sunder R, et al
    CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer.
    Br J Cancer. 2026 Apr 22. doi: 10.1038/s41416-026-03388.
    PubMed     Abstract available
    
    
    
20. WANG DY, Jiang Z, Ben-David Y, Done SJ, et al
    TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression.
    Br J Cancer. 2026 Apr 16. doi: 10.1038/s41416-026-03419.
    PubMed     Abstract available
    
    
    
21. XIE X, Lee J, Gi YJ, Poullikkas T, et al
    ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.
    Br J Cancer. 2026 Apr 15. doi: 10.1038/s41416-026-03413.
    PubMed     Abstract available
    
    
    
22. WANG Z, Ingebriktsen LM, Bekkhus T, Ma L, et al
    Podoplanin-defined tumour plasticity and CCR7-mediated lymphatic metastasis in triple-negative breast cancer.
    Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03402.
    PubMed     Abstract available
    
    
    
23. POUGOUE KETCHEMEN J, Monzer A, Njotu FN, Babeker H, et al
    Potency and safety of novel [(225)Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
    Br J Cancer. 2026 Apr 7. doi: 10.1038/s41416-026-03393.
    PubMed     Abstract available
    
    
    
24. AZAM S, Lamb LR, Eliassen AH, King TA, et al
    Performance of an image-only deep learning breast cancer risk model with the addition of a polygenic risk score.
    Br J Cancer. 2026 Apr 6. doi: 10.1038/s41416-026-03415.
    PubMed     Abstract available
    
    
    
25. FIGUEROA V, Coianis MI, Sahores A, Pataccini G, et al
    Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.
    Br J Cancer. 2026 Apr 4. doi: 10.1038/s41416-026-03420.
    PubMed     Abstract available
    
    
    March 2026
26. ANDERSON J, Lawton S, Thackray K, Kipps E, et al
    Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial.
    Br J Cancer. 2026 Mar 30. doi: 10.1038/s41416-026-03396.
    PubMed     Abstract available
    
    
    
27. MAVADDAT N, Barnes DR, Michailidou K, Zhao E, et al
    Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis.
    Br J Cancer. 2026 Mar 30. doi: 10.1038/s41416-026-03365.
    PubMed     Abstract available
    
    
    
28. KOKTS-PORIETIS RL, Morielli AR, Yang L, Matthews CE, et al
    Associations of health-related fitness and physical activity with chemotherapy outcomes in breast cancer.
    Br J Cancer. 2026 Mar 27. doi: 10.1038/s41416-026-03384.
    PubMed     Abstract available
    
    
    
29. AZAM S, An A, Kensler KH, Weiner MG, et al
    The impact of social drivers of health on delayed time to breast cancer surgery.
    Br J Cancer. 2026 Mar 14. doi: 10.1038/s41416-026-03380.
    PubMed     Abstract available
    
    
    
30. JIANG H, Livingston M, Room R, Kibret AA, et al
    Alcohol consumption and mortality from four alcohol-related cancers in Australia 1950-2018: a time series analysis.
    Br J Cancer. 2026;134:914-923.
    PubMed     Abstract available
    
    
    February 2026
31. KYE YH, Moon SJ, Cha HR, Kim TH, et al
    ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer.
    Br J Cancer. 2026 Feb 24. doi: 10.1038/s41416-026-03347.
    PubMed     Abstract available
    
    
    
32. SHAABAN AE, Jourdain H, Desplas D, Vignot S, et al
    Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.
    Br J Cancer. 2026 Feb 5. doi: 10.1038/s41416-026-03346.
    PubMed     Abstract available
    
    
    January 2026
33. PRAUD D, Amadou A, Mercoeur B, Duboeuf M, et al
    Long-term atmospheric exposure to particulate matter and breast cancer risk: findings from a nested case-control study in France.
    Br J Cancer. 2026 Jan 13. doi: 10.1038/s41416-025-03311.
    PubMed     Abstract available
    
    
    
34. VALASAKI M, Taylor LC, Woof VG, Howell SJ, et al
    The breast cancer risk assessment pathway in England: a systems analysis of current challenges and ways to improve.
    Br J Cancer. 2026 Jan 6. doi: 10.1038/s41416-025-03329.
    PubMed     Abstract available
    
    
    
35. MICHAEL S, Broggio J, Bowers S, Ooi J, et al
    Distant recurrence and margin involvement in invasive breast cancer.
    Br J Cancer. 2026 Jan 5. doi: 10.1038/s41416-025-03275.
    PubMed     Abstract available
    
    
    
36. POURALI G, Matthew KA, Jeon MS, Luo C, et al
    Steroid hormone metabolites and mammographic breast density in premenopausal women.
    Br J Cancer. 2026;134:225-236.
    PubMed     Abstract available
    
    
    December 2025
37. DE SOUZA WAGNER PH, Matheus GTFU, Monteiro Ribeiro D, Figueroa Magalhaes MC, et al
    Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis.
    Br J Cancer. 2025 Dec 23. doi: 10.1038/s41416-025-03320.
    PubMed     Abstract available
    
    
    
38. GUPTA K, Koelsch N, Neely V, Graham L, et al
    Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.
    Br J Cancer. 2025 Dec 15. doi: 10.1038/s41416-025-03292.
    PubMed     Abstract available
    
    
    
39. MA J, Sun S, Tang X, Wang J, et al
    Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.
    Br J Cancer. 2025 Dec 9. doi: 10.1038/s41416-025-03287.
    PubMed     Abstract available
    
    
    
40. OH H, Yaghjyan L, Heng YJ, Baker GM, et al
    Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses' Health Study II.
    Br J Cancer. 2025;133:1695-1707.
    PubMed     Abstract available
    
    
    November 2025
41. VEIGA LHS, Gierach GL, Smith SA, Howell RM, et al
    Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors.
    Br J Cancer. 2025 Nov 14. doi: 10.1038/s41416-025-03240.
    PubMed     Abstract available
    
    
    
42. NOVITSKI SI, Jacobsen RL, Roder T, Holm PC, et al
    Breast cancer risk prediction with a modified BOADICEA model in Danish women.
    Br J Cancer. 2025 Nov 12. doi: 10.1038/s41416-025-03247.
    PubMed     Abstract available
    
    
    
43. COCCO P, Bojke C, Hulme C, Hall PS, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis.
    Br J Cancer. 2025 Nov 6. doi: 10.1038/s41416-025-03248.
    PubMed     Abstract available
    
    
    
44. KRAMER CJH, van Wijk LM, Ruano D, Gelpke-Vermeulen S, et al
    Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond.
    Br J Cancer. 2025;133:1199-1207.
    PubMed     Abstract available
    
    
    
45. ZUCKER K, McInerney C, Glaser A, Baxter P, et al
    Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.
    Br J Cancer. 2025;133:1137-1144.
    PubMed     Abstract available
    
    
    October 2025
46. RUIZ DE AZUA G, Licaj I, Pinto S, Havas J, et al
    Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study.
    Br J Cancer. 2025 Oct 21. doi: 10.1038/s41416-025-03238.
    PubMed     Abstract available
    
    
    
47. FUJII T, Iwase T, Shen Y, Fukui J, et al
    Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer.
    Br J Cancer. 2025 Oct 18. doi: 10.1038/s41416-025-03197.
    PubMed     Abstract available
    
    
    
48. FAN M, Wu X, Pan D, Du J, et al
    Multiscale Pancancer Analysis Uncovers Intrinsic Imaging and Molecular Characteristics Prominent in Breast Cancer and Glioblastoma.
    Br J Cancer. 2025 Oct 15. doi: 10.1038/s41416-025-03235.
    PubMed     Abstract available
    
    
    
49. CHEN X, Cao L, Feng M, Shuai Q, et al
    Breast cancer cell-derived adrenomedullin confers cancer-associated adipose remodeling through the cAMP/Creb1/Zeb1 axis.
    Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03219.
    PubMed     Abstract available
    
    
    
50. TUMANOVA K, Khorasani M, Nofech-Mozes S, Vitkin A, et al
    Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy.
    Br J Cancer. 2025 Oct 3. doi: 10.1038/s41416-025-03150.
    PubMed     Abstract available
    
    
    
51. LIU Y, Fan L, Ye F, Zhao Y, et al
    Androgen receptor interacts with c-Myc to regulate macrophage-osteoclast axis and drive bone metastasis in triple negative breast cancer.
    Br J Cancer. 2025 Oct 2. doi: 10.1038/s41416-025-03202.
    PubMed     Abstract available
    
    
    
52. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    PubMed     Abstract available
    
    
    
53. THONG MSY, Doege D, Koch-Gallenkamp L, Bertram H, et al
    Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.
    Br J Cancer. 2025;133:831-843.
    PubMed     Abstract available
    
    
    
54. LIANG H, Benard O, Kumar V, Griffen A, et al
    Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation.
    Br J Cancer. 2025;133:986-1002.
    PubMed     Abstract available
    
    
    September 2025
55. CUZICK J, Dowsett M
    Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.
    Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03115.
    PubMed     Abstract available
    
    
    
56. STEGGALL J, Rajeeve V, Al-Subaie N, Naeem A, et al
    Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer.
    Br J Cancer. 2025 Sep 13. doi: 10.1038/s41416-025-03174.
    PubMed     Abstract available
    
    
    
57. WOYTASH JA, Lefebvre AEYT, Zhang Z, Xu B, et al
    CDCP1/mitochondrial Src axis increases electron transport chain function to promote metastasis in triple-negative breast cancer.
    Br J Cancer. 2025 Sep 4. doi: 10.1038/s41416-025-03163.
    PubMed     Abstract available
    
    
    
58. WANG T, Zeleznik OA, McGee EE, Brantley KD, et al
    Prospective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women.
    Br J Cancer. 2025 Sep 4. doi: 10.1038/s41416-025-03159.
    PubMed     Abstract available
    
    
    
59. DUSTIN D, Gu G, Beyer AR, Herzog SK, et al
    Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
    Br J Cancer. 2025 Sep 1. doi: 10.1038/s41416-025-03096.
    PubMed    
    
    
    August 2025
60. WU Y, Zhou L, Zhao J, Peng Y, et al
    Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.
    Br J Cancer. 2025 Aug 26. doi: 10.1038/s41416-025-03146.
    PubMed     Abstract available
    
    
    
61. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03038.
    PubMed    
    
    
    
62. JING Y, Wu Y, Hu Q, Wu W, et al
    Remodelling hypoxic TNBC microenvironment restores antitumor efficacy of Vgamma9Vdelta2 T cell therapy.
    Br J Cancer. 2025;133:365-380.
    PubMed     Abstract available
    
    
    July 2025
63. HARVIE M, Pegington M, Howell A, Lim Y, et al
    Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer.
    Br J Cancer. 2025 Jul 31. doi: 10.1038/s41416-025-03129.
    PubMed     Abstract available
    
    
    
64. SOLMUNDE E, Pedersen RN, Norgaard M, Mellemkjaer L, et al
    Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up.
    Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03112.
    PubMed     Abstract available
    
    
    
65. FICORELLA L, Yang X, Mavaddat N, Carver T, et al
    Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117.
    PubMed     Abstract available
    
    
    
66. ALLEN G, Heiland EG, Teleka S, Glimelius I, et al
    Association of change in physical activity with use of outpatient specialist care and hospitalisations among breast cancer survivors with type 2 diabetes in Sweden.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03099.
    PubMed     Abstract available
    
    
    
67. SHIEN T, Hara F, Aogi K, Yanagida Y, et al
    Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03097.
    PubMed     Abstract available
    
    
    
68. FLAHERTY RL, Falcinelli M, Hesketh AR, Patel BA, et al
    Biomarkers of psychological stress are associated with increased susceptibility to the development of breast and prostate cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03085.
    PubMed     Abstract available
    
    
    June 2025
69. BARRAUD S, Vacher S, Schiffler C, Wong J, et al
    Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03083.
    PubMed     Abstract available
    
    
    
70. SCOTT OW, Tin Tin S, Cavadino A, Elwood JM, et al
    Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03070.
    PubMed     Abstract available
    
    
    May 2025
71. PIMENTEL-PARRA GA, Garcia-Vivar C, Escalada-Hernandez P, San Martin-Rodriguez L, et al
    Systematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations.
    Br J Cancer. 2025 May 17. doi: 10.1038/s41416-025-03059.
    PubMed     Abstract available
    
    
    
72. TYRAKIS PA, Kampjut D, Steele GF, Lindstrom HJG, et al
    Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
    Br J Cancer. 2025 May 13. doi: 10.1038/s41416-025-03035.
    PubMed     Abstract available
    
    
    
73. KOTSOPOULOS J, Maxwell CA, Lubinski J, Huzarski T, et al
    Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant.
    Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03029.
    PubMed     Abstract available
    
    
    
74. ABUDULA M, Astuti Y, Raymant M, Sharma V, et al
    Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA.
    Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03013.
    PubMed     Abstract available
    
    
    April 2025
75. PU Y, Xu F, He A, Li R, et al
    Repurposing chlorpromazine for the treatment of triple-negative breast cancer growth and metastasis based on modulation of mitochondria-mediated apoptosis and autophagy/mitophagy.
    Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02992.
    PubMed     Abstract available
    
    
    
76. PETERS J, van Leeuwen MM, Moriakov N, van Dijck JAAM, et al
    Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.
    Br J Cancer. 2025 Apr 6. doi: 10.1038/s41416-025-02995.
    PubMed     Abstract available
    
    
    
77. BUIJS SM, Jongbloed EM, van Bergen LEM, Ramakers CRB, et al
    Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.
    Br J Cancer. 2025;132:525-532.
    PubMed     Abstract available
    
    
    March 2025
78. CAIAZZA F, McGowan PM, Mullooly M, Murray A, et al
    Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
    Br J Cancer. 2025 Mar 14. doi: 10.1038/s41416-025-02973.
    PubMed    
    
    
    
79. SKRIVER C, Cronin-Fenton D, Borgquist S, Hansen Viuff J, et al
    Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study.
    Br J Cancer. 2025 Mar 8. doi: 10.1038/s41416-025-02974.
    PubMed     Abstract available
    
    
    
80. STEINDL A, Zach C, Berchtold L, Grisold A, et al
    Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.
    Br J Cancer. 2025 Mar 1. doi: 10.1038/s41416-025-02967.
    PubMed     Abstract available
    
    
    February 2025
81. ELLIOTT H, Allen AJ, Forester ND, Graziadio S, et al
    Women's perspectives of molecular breast imaging: a qualitative study.
    Br J Cancer. 2025;132:276-282.
    PubMed     Abstract available
    
    
    January 2025
82. VILLETTE CC, Dupuy N, Brightman FA, Zimmermann A, et al
    Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.
    Br J Cancer. 2025 Jan 28. doi: 10.1038/s41416-024-02935.
    PubMed     Abstract available
    
    
    December 2024
83. WU X, Ling Y, Zhang S, Zhang B, et al
    Advancing radiomics from contrast-enhanced mammography in breast cancer.
    Br J Cancer. 2024 Dec 12. doi: 10.1038/s41416-024-02932.
    PubMed    
    
    
    
84. WANG Q, Yu Y, Wang C, Jiang Z, et al
    Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer.
    Br J Cancer. 2024 Dec 10. doi: 10.1038/s41416-024-02917.
    PubMed     Abstract available
    
    
    November 2024
85. WANG W, Wang X, Jiang Y, Guo Y, et al
    Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.
    Br J Cancer. 2024 Nov 28. doi: 10.1038/s41416-024-02906.
    PubMed     Abstract available
    
    
    
86. LUIJENDIJK MJ, Buijs SM, Jager A, Koolen SLW, et al
    Effects of tamoxifen on cognitive function in patients with primary breast cancer.
    Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02914.
    PubMed     Abstract available
    
    
    
87. GIRITHAR HN, Krishnamurthy S, Carroll L, Guller A, et al
    Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02889.
    PubMed     Abstract available
    
    
    
88. SUN Y, Huo D
    Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02905.
    PubMed    
    
    
    
89. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Correction: Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Nov 11. doi: 10.1038/s41416-024-02886.
    PubMed    
    
    
    
90. KAUFMANN M, Vaysse PM, Savage A, Kooreman LFS, et al
    Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study.
    Br J Cancer. 2024;131:1298-1308.
    PubMed     Abstract available
    
    
    
91. TORR B, Jones C, Kavanaugh G, Hamill M, et al
    BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial.
    Br J Cancer. 2024;131:1506-1515.
    PubMed     Abstract available
    
    
    
92. WANG S, Wang T, Guo S, Zhu S, et al
    Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.
    Br J Cancer. 2024;131:1613-1622.
    PubMed     Abstract available
    
    
    October 2024
93. ZHAO T, Xu S, Ping J, Jia G, et al
    A proteome-wide association study identifies putative causal proteins for breast cancer risk.
    Br J Cancer. 2024 Oct 28. doi: 10.1038/s41416-024-02879.
    PubMed     Abstract available
    
    
    
94. EGELAND EV, Seip K, Skourti E, Oy GF, et al
    The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02875.
    PubMed     Abstract available
    
    
    
95. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Oct 7. doi: 10.1038/s41416-024-02846.
    PubMed     Abstract available
    
    
    
96. SABLIN MP, Gestraud P, Jonas SF, Lamy C, et al
    Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
    Br J Cancer. 2024;131:1060-1067.
    PubMed     Abstract available
    
    
    
97. CHIGUCHI G, Cho H
    What kind of tumour rupture requires adjuvant therapy?
    Br J Cancer. 2024;131:1109-1110.
    PubMed    
    
    
    September 2024
98. CASTRO-ESPIN C, Cairat M, Navionis AS, Dahm CC, et al
    Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
    Br J Cancer. 2024 Sep 28. doi: 10.1038/s41416-024-02858.
    PubMed     Abstract available
    
    
    
99. PRASAD D, Baldelli E, Blais EM, Davis J, et al
    Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.
    Br J Cancer. 2024 Sep 25. doi: 10.1038/s41416-024-02852.
    PubMed     Abstract available
    
    
    
100. PHILLIPS JB, Park SS, Lin CH, Cho J, et al
     SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer.
     Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02853.
     PubMed     Abstract available
     
     
     
101. JAVED SR, Skolariki A, Zameer MZ, Lord SR, et al
     Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
     Br J Cancer. 2024 Sep 9. doi: 10.1038/s41416-024-02833.
     PubMed     Abstract available
     
     
     
102. O'LEARY RL, Duijm LEM, Boersma LJ, van der Sangen MJC, et al
     Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.
     Br J Cancer. 2024;131:852-859.
     PubMed     Abstract available
     
     
     
103. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
     PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
     Br J Cancer. 2024;131:820-831.
     PubMed     Abstract available
     
     
     
104. GRAFINGER OR, Hayward JJ, Meng Y, Geddes-McAlister J, et al
     Cancer cell extravasation requires (i)plectin-mediated delivery of MT1-MMP at invadopodia.
     Br J Cancer. 2024;131:931-943.
     PubMed     Abstract available
     
     
     August 2024
105. ARUN B, Couch FJ, Abraham J, Tung N, et al
     BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.
     Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02827.
     PubMed     Abstract available
     
     
     
106. ZOU R, Loke SY, Tang YC, Too HP, et al
     Correction: Development and validation of a circulating microRNA panel for the early detection of breast cancer.
     Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02800.
     PubMed    
     
     
     
107. JOHNSON N, Bentley J, Wang LZ, Newell DR, et al
     Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
     Br J Cancer. 2024 Aug 19. doi: 10.1038/s41416-024-02813.
     PubMed    
     
     
     
108. YUAN J, Xiao M, Zheng Q
     Comment on: "A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures".
     Br J Cancer. 2024 Aug 1. doi: 10.1038/s41416-024-02807.
     PubMed    
     
     
     July 2024
109. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
     Correction: Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
     Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02791.
     PubMed    
     
     
     
110. BESSE A, Sedlarikova L, Buechler L, Kraus M, et al
     HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
     Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02774.
     PubMed     Abstract available
     
     
     
111. YAGHJYAN L, Heng YJ, Baker GM, Murthy D, et al
     Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.
     Br J Cancer. 2024;131:325-333.
     PubMed     Abstract available
     
     
     June 2024
112. POSSENTI I, Scala M, Carreras G, Bagnardi V, et al
     Exposure to second-hand smoke and breast cancer risk in non-smoking women: a comprehensive systematic review and meta-analysis.
     Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02732.
     PubMed     Abstract available
     
     
     
113. BOMAN C, Liu X, Eriksson Bergman L, Sun W, et al
     A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.
     Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02777.
     PubMed     Abstract available
     
     
     
114. ZHU T, Huang YH, Li W, Wu CG, et al
     A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.
     Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02726.
     PubMed     Abstract available
     
     
     
115. POUMEAUD F, Morisseau M, Cabel L, Goncalves A, et al
     Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
     Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02766.
     PubMed     Abstract available
     
     
     
116. ZUO W, Wang Z, Qian J, Ma X, et al
     QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controll
     Br J Cancer. 2024 Jun 21. doi: 10.1038/s41416-024-02751.
     PubMed     Abstract available
     
     
     
117. RYU H, Shin KH, Chang JH, Jang BS, et al
     A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures.
     Br J Cancer. 2024 Jun 5. doi: 10.1038/s41416-024-02741.
     PubMed     Abstract available
     
     
     
118. TSOULAKI O, Tischkowitz M, Antoniou AC, Musgrave H, et al
     Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
     Br J Cancer. 2024;130:2027-2036.
     PubMed     Abstract available
     
     
     May 2024
119. TREEKITKARNMONGKOL W, Shah V, Kai K, Katayama H, et al
     Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
     Br J Cancer. 2024 May 17. doi: 10.1038/s41416-024-02697.
     PubMed     Abstract available
     
     
     
120. HAM B, Kim SY, Kim YA, Han D, et al
     Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
     Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02707.
     PubMed     Abstract available
     
     
     
121. STOER NC, Vangen S, Singh D, Fortner RT, et al
     Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
     Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
     PubMed     Abstract available
     
     
     
122. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
     Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
     Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02703.
     PubMed     Abstract available
     
     
     
123. SHEN F, Jiang G, Philips S, Cantor E, et al
     Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
     Br J Cancer. 2024;130:1348-1355.
     PubMed     Abstract available
     
     
     
124. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
     The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
     Br J Cancer. 2024;130:1875-1884.
     PubMed     Abstract available
     
     
     April 2024
125. HANNA D, Merrick S, Ghose A, Devlin MJ, et al
     Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
     Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02685.
     PubMed     Abstract available
     
     
     
126. CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al
     Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
     Br J Cancer. 2024 Apr 18. doi: 10.1038/s41416-024-02680.
     PubMed     Abstract available
     
     
     
127. BRAUN M, Piasecka D, Sadej R, Romanska HM, et al
     FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
     Br J Cancer. 2024 Apr 17. doi: 10.1038/s41416-024-02658.
     PubMed     Abstract available
     
     
     
128. ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
     Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
     Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
     PubMed     Abstract available
     
     
     
129. ALEXANDER J, Schipper K, Nash S, Brough R, et al
     Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
     Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
     PubMed     Abstract available
     
     
     March 2024
130. LIU X, Cheng X, Xie F, Li K, et al
     Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
     Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02610.
     PubMed     Abstract available
     
     
     
131. TEN VELDE DE, Duijm LEM, van der Sangen MJC, Schipper RJ, et al
     Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme.
     Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02633.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum